Skip to content
Home/Companies/Biotech/Bambusa Therapeutics

Bambusa Therapeutics

Biotech·US·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Bambusa Therapeutics?

Bambusa Therapeutics is currently owned by Athos through Athos Evergreen Life Sciences (2001 vintage), since 2025.

Hand-verified · updated 2026-07-07

Athos
Investor
Athos
Athos Evergreen Life Sciences · 2001 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Athos Evergreen Life Sciences

Other portfolio companies in the same fund.

Doctolib
Doctolib
Active
FintechFrance· 2026
AAVantgarde Bio
Active
BiotechItaly· 2025
AMSilk
Active
BiotechGermany· 2025
Antheia
Active
BiotechUS· 2025
NexWafe
NexWafe
Active
EnergyGermany· 2023
Formycon
Formycon
Active
BiotechGermany· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Bambusa Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Bambusa Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Bambusa Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue